NEWS ALERT SIGNUP STAY IN TOUCH HOME OUR COMPANY PRODUCT PORTFOLIO INVESTORS PRESS RELEASES CAREERS CONTACT Improving lives with innovative value-added medicines Welcome to the Hyloris investor relations pages. Creating value by rethinking and reinventing existing medications Our ambition is to develop added-value medicines based on known pharmaceuticals to address unmet medical needs and deliver improvements for patients, healthcare professionals and payors. By 2024, our vision is that our portfolio of candidate and commercial value-added products will have grown to 30. Founded in Liège, Belgium in 2012, Hyloris Pharmaceuticals SA’s ordinary shares are listed on Euronext Brussels since June 2020, under the ticker symbol HYL and are included in the Bel Small Cap index. The Hyloris share + View the interactive share price graph, the shareholding structure, and more share related information here. LEARN MORE Financials + Consult our financial reports, the financial calendar, and other documents here. LEARN MORE Our governance + Information about our corporate governance principles, our governance structure and documents can be found here. LEARN MORE Investors toolkit + Access our presentations, reports, webcasts and more here. LEARN MORE Hyloris Pharmaceuticals SA HQ: Boulevard Gustave Kleyer 17, 4000 Liège, Belgium T:+32 (0)4 346 02 07 E:contact@hyloris.com Quick links HOME INVESTORS OUR STRATEGY PRODUCT PORTFOLIO OUR COMPANY PRESS RELEASES CAREERS CONTACT News alert signup Stay updated on the latest developments at Hyloris. NEWS VIA EMAIL 2021 - Hyloris Pharmaceuticals SA - Design & Development by CLICK GDPR - Privacy Policy GDPR - Cookies Policy Terms of website use We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All